Fundraising FoxEmtora Biosciences
1 known investors
Find your way into Emtora Biosciences
Sign up to see every warm intro you have to Emtora Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Emtora Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Emtora Biosciences is a clinical-stage life science company developing eRapa, a novel formulation of rapamycin, to prevent the onset and recurrence of cancer. Its lead program, Serenta (eRapa), is in a Phase 3 trial evaluating safety and efficacy in patients diagnosed with familial adenomatous polyposis (FAP).
Investors · 1
Related companies · 2
Mammoth BiosciencesMammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Emtora Biosciences.
Frequently asked questions
- What does Emtora Biosciences do?
- Emtora Biosciences is a clinical-stage life science company developing eRapa, a novel formulation of rapamycin, to prevent the onset and recurrence of cancer. Its lead program, Serenta (eRapa), is in a Phase 3 trial evaluating safety and efficacy in patients diagnosed with familial adenomatous polyposis (FAP).
- Who are Emtora Biosciences's investors?
- Emtora Biosciences's investors include UT Horizon Fund.